108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
瑞马唑仑在脆弱人群中的安全性
Authors Ge JY, Deng BR , Cao XH, Liu XJ
Received 26 April 2025
Accepted for publication 14 September 2025
Published 25 September 2025 Volume 2025:19 Pages 8691—8709
DOI https://doi.org/10.2147/DDDT.S536873
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Georgios Panos
Jia-Yi Ge,* Bo-Ran Deng,* Xiao-Hua Cao, Xing-Jun Liu
School of Pharmacy, Nantong University, Nantong, Jiangsu, 226019, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xing-Jun Liu, School of Pharmacy, Nantong University, No. 9 Se Yuan Road, Nantong, Jiangsu, People’s Republic of China, Tel/Fax +86-0513-5500-3425, Email edvin201@163.com
Abstract: Vulnerable populations require careful consideration in drug selection due to their unique physiological conditions. Remimazolam, an innovative ultra-short-acting benzodiazepine, presents several advantages, including rapid onset, brief duration of action, and high predictability. Despite the extensive literature on remimazolam, few studies have specifically evaluated its safety in vulnerable patient populations. This review offers a comprehensive analysis of the safety profile of remimazolam in vulnerable populations, including cardiovascular diseases, neurological disorders, hepatic and renal dysfunction, respiratory conditions, metabolic disorders, rare diseases, and special groups such as the elderly and pediatric patients. It assesses recovery outcomes, hemodynamic stability, and adverse events such as respiratory depression and delirium. In our view, the prophylactic potential of remimazolam in these aspects may not be inferior to traditional anesthetic drugs (propofol, sevoflurane, etomidate, etc). and shows a trend of surpassing them in some aspects.
Keywords: hemodynamic stability, recovery outcomes, respiratory depression, delirium
School of Pharmacy, Nantong University, Nantong, Jiangsu, 226019, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xing-Jun Liu, School of Pharmacy, Nantong University, No. 9 Se Yuan Road, Nantong, Jiangsu, People’s Republic of China, Tel/Fax +86-0513-5500-3425, Email edvin201@163.com
Abstract: Vulnerable populations require careful consideration in drug selection due to their unique physiological conditions. Remimazolam, an innovative ultra-short-acting benzodiazepine, presents several advantages, including rapid onset, brief duration of action, and high predictability. Despite the extensive literature on remimazolam, few studies have specifically evaluated its safety in vulnerable patient populations. This review offers a comprehensive analysis of the safety profile of remimazolam in vulnerable populations, including cardiovascular diseases, neurological disorders, hepatic and renal dysfunction, respiratory conditions, metabolic disorders, rare diseases, and special groups such as the elderly and pediatric patients. It assesses recovery outcomes, hemodynamic stability, and adverse events such as respiratory depression and delirium. In our view, the prophylactic potential of remimazolam in these aspects may not be inferior to traditional anesthetic drugs (propofol, sevoflurane, etomidate, etc). and shows a trend of surpassing them in some aspects.
Keywords: hemodynamic stability, recovery outcomes, respiratory depression, delirium